# Protein Engineering Market

> Protein Engineering Market Research Report: Size, Share, Trend Analysis By Types (Instrument, Reagent, and Services & Software), By Applications (Food & Detergent Industries, Environment, Medical, Biopolymer Production, and Nano Biotechnology), By Method (Rational Protein Design, Directed, and Evolution), By End Users (Pharmaceutical & Biotechnology Companies, Contract Engineering Organizations, and Academic Research Institutes), and By Region (North America, Europe, Asia-Pacific, and Rest Of The World) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 11.8%
- **2024:** $ 1,900.63 Million
- **2025:** $ 2,124.95 Million
- **2035:** $ 6,484.03 Million
- **Key Players:** Companies such as Amgen (US), Genentech (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), GSK (GB), Merck & Co. (US), Novartis (CH), Pfizer (US), Roche (CH) are some of the major participants in the global market.

**Report ID:** MRFR/HC/0220-CR · **Pages:** 132 · **Author:** Rahul Gotadki & Kinjoll Dey · **Last Updated:** June 26, 2026

**URL:** https://www.marketresearchfuture.com/reports/protein-engineering-market-691

---

## Market Summary

## **Protein Engineering Market Overview**

As per MRFR analysis, the Protein Engineering Market Size was estimated at 1.90 (USD Billion) in 2024. The Protein Engineering Market Industry is expected to grow from 2.12 (USD Billion) in 2025 to 5.80 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 11.80% during the forecast period (2025 - 2034).Chronic diseases are becoming more prevalent, and synthetic biology is receiving more funding, which are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, _Market Research Future_ Database, and Analyst Review

In June 2024, Daicel Arbor Biosciences is pleased to announce the launch of the latest version of their myTXTL® kits. These kits are used for cell-free protein production and are specifically designed to streamline and expedite the process of discovering antibodies and designing proteins. The myTXTL Pro Kit and the myTXTL Antibody/DS Kit are advanced kits that offer researchers versatile tools to increase the efficiency of their protein expression platforms. 

These kits are designed to elevate the performance of discovery programs in both industry and academia. The myTXTL Pro Kit provides researchers with a very efficient method for expressing proteins that do not include disulfide bonds. It consolidates all the advantages of our prior kit options into a single package, making it a more convenient and reliable alternative. The Pro Kit is versatile and can be used for several applications in protein expression and synthetic biology, such as doing a basic library screen, performing CRISPR-Cas activity experiments, or testing gene circuits.

In June 2024, Brevel, Ltd., a company specializing in microalgae protein, inaugurated its inaugural commercial facility. The new facility spans an area of 27,000 square feet (equivalent to 2,500 square meters) and has the capability to manufacture hundreds of tons of microalgae protein powder. Situated on the outskirts of Israel's desert, the new facility is designed to expedite the entry of Brevel's novel plant protein into the commercial food industry by scaling up production to industrial levels. 

Brevel claims that it can offer a novel protein supply derived from specially cultivated microalgae of the chlorella genus, using its newly established facilities. The final ingredient is said to be extremely healthy, containing a complete amino acid profile while also being cost-effective. The state-of-the-art facility includes cutting-edge bioproduction laboratories, expansive workspaces, a contemporary food application laboratory, and state-of-the-art quality control technology. 

## **Protein Engineering Market Trends**

Market CAGR for protein engineering is being driven by the rising need for treatments and medications based on proteins over the forecast period, and market for protein engineering, which is extremely dependent on the rising need for proteins made from proteins. Biologics, or proteins-based medications, treat various illnesses like cancer, autoimmune conditions, and uncommon genetic disorders. Drugs based on proteins have several benefits over conventional small-molecule medications. As they are created to interact with particular targets in the body, they are frequently more selective and have fewer adverse effects.

Additionally, protein-based medications have a lower likelihood of being metabolized by the liver, which can increase their effectiveness and lower the possibility of toxicity. These benefits have led to a huge increase in the demand for protein-based medicines on the international market. Many variables, such as the rising prevalence of chronic diseases, aging populations, and rising healthcare costs, influence this rise. The desire for new and improved therapeutics is mostly driven by the increased prevalence of chronic diseases like cancer, diabetes, and cardiovascular problems.

In addition, it is projected that the market would grow significantly as a result of the rising number of government programmes meant to advance the field of protein engineering. As a result, there has been a growth in this field's R&D spending, amount of funds awarded, and research and development programs. For instance, Nabla Bio reported that a USD 11 million seed fundraising round would be completed in December 2021. With the aid of this funding, a platform for AI-first design will be created, paving the way for new antibody therapies.

Likewise, Generate Biomedicines, and Amgen confirmed A research partnership agreement to create protein therapeutics for 5 clinical targets in January 2022. The demand for protein engineering is being driven by the rise in chronic & lifestyle diseases like diabetes, cardiovascular disorders, and others. As a result, it is anticipated that the demand for protein engineering will increase throughout the projection period due to the high demand for treatments and medications. Thus, driving the protein engineering market revenue.

## **Protein Engineering Market Segment Insights**

### **Protein Engineering Type Insights**

The market segments of protein engineering, based on type, includes instruments, reagents, and services & software. The instrumentS segment dominated the market, accounting for 51.50% of market revenue (0.77 Billion). Demand for this market segment is being driven by the growing preference among researchers for automated methods for encouraging quick molecular development processes.

### **Protein Engineering Application Insights**

The protein engineering market segmentation, based on application, includes food & detergent Industries, environment, medical, biopolymer production, and

[nanobiotechnology](../../../reports/nano-biotechnology-market-10593)

. The nanobiotechnology category generated the most income (35%). This is due to the widespread use of hybrid techniques, which combine directed evolution and rational design, for various purposes, such as improving redox proteins and enzymes. The fabrication of nano-devices for biosensing and other significant nanotechnology engineering applications places a high value on these enzymes, boosting the chances for future growth.

### **Protein Engineering Route Administration Insights**

The market segmentation of protein engineering, based on method, includes rational protein design and directed evolution. The rational protein design segment dominated the market, accounting for 58% of market revenue. The technology's vast application in enzyme engineering and antibody development accounts for the dominant share. Enzyme engineering has seen a tremendous increase in its commercial uses, which has led to the creation of improved and modified enzymes with the appropriate catalytic capabilities.

### **Protein Engineering End User Insights**

The  protein engineering market segmentation, based on end-users, includes pharmaceuticals & biotechnology companies, contract engineering organizations, and academic research institutes. The pharmaceuticals & biotechnology companies segment dominated the market, accounting for 52% of market revenue. The segment is expanding due to more and more in silico drug discovery models being used to treat neurological issues, cancer, and diabetes. These companies continuously attempt to preserve their market position by creating drug versions of patent-expiring pharmaceuticals utilizing a computer modeling technique.

**Figure 1  Protein Engineering Market by End User, 2022 & 2032 (USD Billion)**  **_Source Secondary Research, Primary Research, MRFR Database, and Analyst Review_**

### **Protein Engineering Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American protein engineering market will dominate this market, owing to the presence of numerous market players and their varied strategic efforts.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2 ** **Protein Engineering Market Share By Region 2022 (USD Billion)** ** ** **** ** ** **_Source Secondary Research, Primary Research, MRFR Database, and Analyst Review_**

Europe's Protein Engineering market accounts for the second-largest market share due to the availability of a sizable population base for the development and clinical testing of protein engineering applications. Further, the German market of protein engineering held the largest market share, and the UK market of protein engineering was the second-largest growing market in the European region.

The Asia-Pacific protein engineering market is expected to grow at the fastest CAGR from 2023 to 2032. This is due to the high prevalence of autoimmune, cardiovascular, and cancer diseases in developing Asian nations. Due to the significant economic development in emerging countries like India and China, unexplored potential in this region is also anticipated to help the sector thrive. Moreover, China’s market of protein engineering held the largest market share, and the Indian market of protein engineering was the fastest-growing market in the Asia-Pacific region.

## **Protein Engineering Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the market of protein engineering, grow even more. Market participants are also engaging in a variety of strategic measures in order to grow their businesses  presence, with significant market development such as new product releases, contractual agreements, mergers and acquisitions, increased investments, and so on partnerships with other organisations. The protein engineering industry must offer cost-effective items to expand and survive in a more competitive and developing market condition.

One of the most important company strategies is to manufacture locally to save operational costs. manufacturers use in the  protein engineering industry to benefit clients and increase the market sector. In recent years, the protein engineering industry has provided some of the greatest significant benefits to medicine. Major players in the protein engineering market, including Agilent Technologies (U.S.), AB-Sciex (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Bruker Corp. (U.S.), GE Healthcare (U.K.), Perkin Elmer (U.S.), Sigma-Aldrich Corp. (U.S.), Thermo Fisher Scientific (U.S.), and Waters Corp. (U.S).

Agilent Technologies, Inc. offers fundamental bio-analytical and electronic measurement solutions to the chemical analysis, communications, electronics, and life sciences industries. The business provides semiconductor and board testing and electronic and bioanalytical measurements. In October 2020, The Agilent Seahorse XFp Analyzer, a device for assessing metabolic activity in living cells that can be utilized in protein engineering research, was introduced by Agilent Technologies.

AbbVie Inc. researches and develops pharmaceutical products. The company produces pharmaceutical medications for specialized treatment fields like immunology, chronic renal disease, hepatitis C, women's health, oncology, and neuroscience. Multiple sclerosis, Parkinson's, and

[Alzheimer's disease](../../../reports/alzheimers-disease-diagnostic-market-2149)

are just a few of the illnesses that AbbVie treats. In March 2022, for treating moderately to highly active ulcerative colitis, the U.S. FDA gave AbbVie Inc. permission to use RINVOQ (upadacitinib), a new medication.

### **Key Companies in the market of Protein Engineering include**

## Protein Engineering Industry Developments

- **Q2 2024: GenScript Launches New Protein Engineering Platform to Accelerate Antibody Drug Discovery** GenScript Biotech announced the launch of its next-generation protein engineering platform designed to streamline and accelerate the discovery and optimization of antibody therapeutics, offering enhanced capabilities for pharmaceutical partners.
- **Q2 2024: Codexis Announces Strategic Partnership with Nestlé Health Science for Enzyme Engineering** Codexis entered into a multi-year collaboration with Nestlé Health Science to engineer novel enzymes for use in medical nutrition products, leveraging Codexis’s protein engineering expertise to develop customized solutions.
- **Q2 2024: Thermo Fisher Scientific Opens New Protein Engineering Center in Massachusetts** Thermo Fisher Scientific inaugurated a state-of-the-art protein engineering facility in Massachusetts, aimed at expanding its capabilities in biologics development and supporting pharmaceutical clients with advanced protein design services.
- **Q3 2024: Bruker Acquires Protein Engineering Startup Evozyne for $150 Million** Bruker announced the acquisition of Evozyne, a Chicago-based protein engineering company specializing in AI-driven enzyme design, to strengthen its biopharma solutions portfolio.
- **Q3 2024: Danaher Launches Protein Engineering Innovation Hub in Switzerland** Danaher Corporation opened a new innovation hub in Switzerland focused on protein engineering, aiming to foster collaboration with European biotech firms and accelerate the development of next-generation biologics.
- **Q3 2024: Absci Raises $100 Million in Series D Funding to Expand AI Protein Engineering Platform** Absci secured $100 million in Series D financing to scale its AI-powered protein engineering platform, with the goal of accelerating drug discovery partnerships with major pharmaceutical companies.
- **Q4 2024: Eli Lilly and Company Announces FDA Approval for Engineered Insulin Analog** Eli Lilly received FDA approval for its newly engineered insulin analog, developed using advanced protein engineering techniques to improve efficacy and reduce dosing frequency for diabetes patients.
- **Q4 2024: GenScript and Merck KGaA Enter Strategic Collaboration for Protein Therapeutics** GenScript Biotech and Merck KGaA announced a strategic partnership to co-develop engineered protein therapeutics, combining GenScript’s protein engineering platforms with Merck’s clinical development expertise.
- **Q1 2025: Novo Nordisk Opens New Protein Engineering R&D Center in Denmark** Novo Nordisk inaugurated a new research and development center dedicated to protein engineering in Denmark, aiming to accelerate the discovery of next-generation protein-based therapeutics for metabolic diseases.
- **Q1 2025: Thermo Fisher Scientific Acquires Protein Engineering Firm Ingenza** Thermo Fisher Scientific completed the acquisition of Ingenza, a UK-based protein engineering company, to enhance its synthetic biology and enzyme engineering capabilities for biopharmaceutical manufacturing.
- **Q2 2025: ElevateBio Announces $200 Million Series C Funding to Advance Cell and Protein Engineering Platforms** ElevateBio raised $200 million in Series C funding to expand its cell and protein engineering platforms, supporting the development of novel gene and cell therapies.
- **Q2 2025: Bio-Rad Laboratories Appoints New Head of Protein Engineering Division** Bio-Rad Laboratories announced the appointment of Dr. Maria Chen as the new head of its protein engineering division, signaling a strategic focus on expanding its biologics and enzyme engineering business.

## **Protein Engineering Market Segmentation**

### **Protein Engineering Type Outlook**

### **Protein Engineering Application Outlook**

### **Protein Engineering Method Outlook**

### **Protein Engineering End User Outlook**

### **Protein Engineering Regional Outlook**

**North America**

**Europe**

**Asia-Pacific**

**Rest of the World**

## Market Drivers

### Market Growth Projections

The Global Protein Engineering Market Industry is projected to experience substantial growth in the coming years. With a market value of 1.9 USD Billion in 2024, it is anticipated to reach 6.48 USD Billion by 2035, reflecting a robust CAGR of 11.81% from 2025 to 2035.
 
This growth trajectory is indicative of the increasing importance of protein engineering across various sectors, including pharmaceuticals, agriculture, and industrial applications. The market's expansion is likely to be driven by ongoing technological advancements, rising demand for [biopharmaceuticals](https://www.marketresearchfuture.com/reports/biopharmaceuticals-market-8439), and the growing recognition of engineered proteins' potential to address complex challenges in health and industry.

### Regulatory Support and Frameworks

Regulatory support is an essential factor influencing the Global Protein Engineering Market Industry. Governments worldwide are establishing frameworks that facilitate the approval and commercialization of engineered proteins, particularly in the biopharmaceutical sector. These regulations aim to ensure safety and efficacy while promoting innovation.
 
The establishment of clear guidelines encourages investment and research, as companies are more likely to engage in protein engineering initiatives when regulatory pathways are well-defined. This supportive environment is likely to enhance the market's growth, as it fosters collaboration between regulatory bodies and industry stakeholders, ultimately benefiting public health.

### Rising Demand for Biopharmaceuticals

The Global Protein Engineering Market Industry is experiencing a notable surge in demand for biopharmaceuticals, driven by advancements in personalized medicine and targeted therapies. As of 2024, the market is valued at approximately 1.9 USD Billion, reflecting the increasing reliance on engineered proteins for drug development.
 
This trend is expected to continue, with projections indicating a market growth to 6.48 USD Billion by 2035. The compound annual growth rate (CAGR) of 11.81% from 2025 to 2035 underscores the potential of protein engineering in producing innovative therapeutics that cater to specific patient needs.

### Growing Applications in Industrial Biotechnology

The Global Protein Engineering Market Industry is witnessing an expansion in applications beyond healthcare, particularly in industrial biotechnology. Engineered proteins are increasingly utilized in various sectors, including agriculture, food production, and environmental management. For example, enzymes developed through protein engineering are employed in biofuels and bioremediation processes, showcasing their versatility.
 
This diversification of applications is expected to contribute to the market's growth trajectory, as industries seek sustainable and efficient solutions. The ongoing exploration of protein engineering in industrial contexts suggests a promising future for the market, with potential for significant economic impact.

### Increasing Investment in Research and Development

Investment in research and development is a critical driver for the Global Protein Engineering Market Industry. Governments and private entities are allocating substantial resources to explore the therapeutic applications of engineered proteins. This trend is evident in various initiatives aimed at fostering innovation in biotechnology.
 
For instance, funding programs targeting protein engineering research have been established, leading to breakthroughs in [drug discovery and development](https://www.marketresearchfuture.com/reports/drug-discovery-informatics-market-7831). The anticipated growth of the market from 1.9 USD Billion in 2024 to 6.48 USD Billion by 2035 highlights the importance of sustained investment in R&D, which is essential for advancing the field and addressing unmet medical needs.

### Technological Advancements in Protein Engineering

Technological innovations play a pivotal role in shaping the Global Protein Engineering Market Industry. The advent of high-throughput screening and computational modeling techniques has revolutionized the way proteins are engineered. These advancements facilitate the rapid identification and optimization of protein structures, enhancing their efficacy and stability.
 
As a result, companies are increasingly investing in research and development to harness these technologies, thereby driving market growth. The integration of artificial intelligence and machine learning into protein design processes further amplifies the potential for creating novel proteins with desirable characteristics, positioning the industry for sustained expansion.

## Future Outlook

The Protein Engineering Market size is projected to reach USD 6,484.03 Million by 2035, growing at a CAGR of 11.8%

**New opportunities:**

- Development of tailored enzymes for industrial applications. Investment in AI-driven protein design platforms. Expansion of biopharmaceutical collaborations for novel drug development.

By 2035, the Protein Engineering Market is expected to be robust, reflecting substantial growth and innovation.

## Segment Insights

### By Application: Therapeutics (Largest) vs. Diagnostics (Fastest-Growing)

The Protein Engineering Market showcases a diverse application landscape with therapeutics occupying the largest share. This segment is primarily driven by increasing investments in biopharmaceuticals and a growing focus on precision medicine, which have collectively strengthened the role of engineered proteins in therapeutic solutions. Following therapeutics, diagnostics represents the fastest-growing segment, fueled by heightened demand for innovative diagnostic tools that leverage engineered proteins to enhance disease detection and monitoring capabilities. As these applications evolve, they reflect the dynamic interplay between technology advancements and market needs. In recent years, the Protein Engineering Market has witnessed substantial growth across its application segments. Factors such as rising healthcare expenditure, an increasing focus on personalized medicine, and the need for advanced diagnostic tools have significantly bolstered the therapeutics and diagnostics segments. Furthermore, the ongoing research initiatives aimed at developing novel industrial enzymes and advancements in agricultural biotechnology are expected to drive future growth. As industries pivot towards sustainable practices, the integration of protein engineering into agricultural applications marks a significant shift, catering to the demand for improved crop yields and resistance to diseases.

Therapeutics (Dominant) vs. Industrial Enzymes (Emerging)

In the Protein Engineering Market, the therapeutics segment stands as the dominant application, primarily due to its crucial role in the development of targeted therapies for various diseases, including cancer and autoimmune disorders. This segment benefits from strong R&D investments and a robust pipeline of biologics that utilize engineered proteins. On the other hand, industrial enzymes are emerging rapidly as a key segment, driven by the increasing need for sustainable industrial processes. These enzymes, engineered for specific applications, are becoming integral in various industries such as biofuels, food processing, and waste management, as they offer eco-friendly solutions that enhance efficiency and reduce costs. The growth of industrial enzymes is expected to gain momentum as more companies adopt green technologies.

### By Technology: Recombinant DNA Technology (Largest) vs. Synthetic Biology (Fastest-Growing)

In the Protein Engineering Market, Recombinant DNA Technology holds the largest share, accounting for a significant chunk of the market's technological advancements. This technology has been pivotal in facilitating the production of proteins with desirable properties, leading to applications in various fields including medicine and agriculture. Other notable segments include Synthetic Biology, which is rapidly gaining traction and is expected to expand due to its innovative approaches to designing and constructing new biological parts, devices, and systems. The growth trends in this segment are driven by increasing R&D efforts in biopharmaceuticals, demand for personalized medicine, and advancements in genomics technologies. Recombinant DNA Technology is well-established and continues to evolve, while Synthetic Biology represents an emerging frontier filled with potential. These dynamics are motivating stakeholders to invest heavily, fueling competition, and driving innovation in the Protein Engineering Market.

Recombinant DNA Technology (Dominant) vs. Directed Evolution (Emerging)

Recombinant DNA Technology is regarded as the dominant force in the market share due to its widespread applications and ability to efficiently produce proteins with specific traits. This technology has revolutionized therapeutics by enabling the creation of biologics that can be tailored for individual patient needs. The segment benefits from robust regulatory frameworks and established protocols, making it a preferred choice among researchers and companies alike. On the other hand, Directed Evolution is an emerging segment characterized by its innovative methods for evolving proteins in the lab, allowing for the rapid optimization of enzyme functions and stability. Despite being less established, it shows great promise in developing next-generation proteins for diverse applications such as biofuels and pharmaceuticals, thus capturing the interest of investors and researchers looking towards more adaptive solutions.

### By End Use: Pharmaceuticals (Largest) vs. Biotechnology (Fastest-Growing)

The Protein Engineering Market is significantly shaped by various end-use segments, with Pharmaceuticals occupying the largest share, owing to its extensive application in drug development and production. Biotechnology follows closely, leveraging advanced techniques to innovate therapeutic solutions, demonstrating a robust share as well. As these sectors grow, others such as Food and Beverage, Agriculture, and Cosmetics also contribute to the overall market dynamics with their respective demands for engineered proteins and bioproducts.

Pharmaceuticals (Dominant) vs. Biotechnology (Emerging)

Pharmaceuticals hold a dominant position in the market share, primarily driven by the increasing demand for biologics and personalized medicine. This segment benefits from advanced biotechnological processes that enhance drug efficacy and safety. In contrast, the Biotechnology sector is emerging rapidly, characterized by its focus on innovation and research in protein synthesis and manipulation. With rising investments in R&D, Biotechnology is well-placed to capitalize on the growing need for novel therapies and treatments, making it a crucial player in the market.

## Regional Market Share Analysis

### North America : Innovation and Leadership Hub

North America leads in the Protein Engineering Market Size, accounting for over 50.0% of the global revenue in 2024. The region's growth is driven by robust investments in biotechnology, increasing demand for [biologics](https://www.marketresearchfuture.com/reports/biologics-market-1339), and supportive regulatory frameworks. The presence of major pharmaceutical companies and research institutions further catalyzes innovation and development in this sector. Regulatory bodies are actively promoting advancements in protein engineering, ensuring a conducive environment for market expansion.

The United States stands out as a key player, hosting industry giants like Amgen, Genentech, and Pfizer. These companies are at the forefront of research and development, contributing to the region's competitive landscape. The collaboration between academia and industry fosters a rich ecosystem for innovation. As the market evolves, North America is expected to maintain its leadership position, driven by continuous advancements in technology and a strong pipeline of new therapies.

### Europe : Emerging Market with Growth Potential

Europe's Protein Engineering Market is poised for growth, with a market size of 600.0M in 2024. The region benefits from a well-established healthcare system and a strong emphasis on research and development. Regulatory frameworks, such as the European Medicines Agency's guidelines, are facilitating the approval of innovative therapies. The increasing focus on biopharmaceuticals and personalized medicine is driving demand, supported by government initiatives aimed at enhancing healthcare outcomes.

Leading countries in Europe include Germany, France, and the UK, which are home to key players like Novo Nordisk and GSK. The germany protein engineering market leads the region due to its strong pharmaceutical base and advanced R&D capabilities. Similarly, the france protein engineering market is expanding with increasing government support and innovation in biologics, while the italy protein engineering market is gaining traction through healthcare investments and biotech collaborations. The competitive landscape is marked by collaborations between academia and industry, fostering innovation. The presence of numerous biotech firms and research institutions enhances the region's capabilities in protein engineering, making it a significant player in the global market.

### Asia-Pacific : Rapidly Growing Market

The Asia-Pacific region is witnessing rapid growth in the Protein Engineering Market, with a market size of 300.0M in 2024. Factors such as increasing investments in biotechnology, a growing patient population, and rising healthcare expenditures are driving this expansion. Governments are implementing favorable policies to attract foreign investments and enhance local capabilities in biopharmaceuticals, which is further catalyzing market growth.

Countries like China, Japan, and India are leading the charge in this region, with a burgeoning number of biotech firms and research institutions. The china protein engineering market is a major growth driver, supported by strong government initiatives, expanding biotech infrastructure, and rising investments in drug discovery. Additionally, the japan protein engineering market is highly advanced, characterized by cutting-edge research and a strong pharmaceutical industry focused on biologics and enzyme engineering. The competitive landscape is evolving, with both local and international players vying for market share. The presence of key companies and a focus on innovation are positioning Asia-Pacific as a significant contributor to the global protein engineering landscape.

### Middle East and Africa : Untapped Market Potential

The Middle East and Africa (MEA) region, with a market size of 50.13M in 2025, presents untapped opportunities in the Protein Engineering sector. The growth is driven by increasing investments in healthcare infrastructure and a rising focus on biotechnology. Governments in the region are recognizing the importance of biopharmaceuticals and are implementing policies to support research and development. The demand for innovative therapies is growing, particularly in response to rising healthcare challenges.

Countries like South Africa and the UAE are emerging as key players, with initiatives aimed at fostering biotech innovation. The competitive landscape is still developing, with a mix of local and international firms. As the region continues to invest in its biotech capabilities, it is poised for significant growth in the protein engineering market, attracting global players looking to expand their footprint.

## Competitive Benchmarking

The Protein Engineering Market is characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for therapeutic proteins. Key players such as Amgen (US), Genentech (US), and Bristol-Myers Squibb (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market positions. Amgen (US) focuses on developing novel biologics, while Genentech (US) emphasizes personalized medicine through targeted therapies. Bristol-Myers Squibb (US) is actively pursuing mergers and acquisitions to expand its portfolio, indicating a trend towards consolidation in the market.
 
Collectively, these strategies contribute to a competitive environment that is increasingly shaped by technological advancements and collaborative efforts. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The Protein Engineering Market appears moderately fragmented, with a mix of established players and emerging biotech firms. The influence of key players is significant, as their strategic initiatives often set industry standards and drive innovation across the sector.
In November Amgen (US) announced a partnership with a leading AI firm to enhance its drug discovery processes. This collaboration aims to integrate artificial intelligence into protein engineering, potentially accelerating the development of new therapeutics. The strategic importance of this move lies in its potential to streamline research and development, thereby reducing time-to-market for innovative treatments.
In October Genentech (US) launched a new platform for protein engineering that utilizes machine learning algorithms to predict protein folding and stability. This initiative is expected to enhance the efficiency of drug development processes, allowing for more rapid advancements in personalized medicine. The significance of this development underscores the growing role of technology in shaping the future of protein engineering.
In September Bristol-Myers Squibb (US) completed the acquisition of a biotech startup specializing in antibody-drug conjugates. This strategic acquisition is likely to bolster its capabilities in targeted therapies, reflecting a broader trend of companies seeking to enhance their therapeutic offerings through strategic investments. Such moves indicate a shift towards more specialized and effective treatment options in the market.
As of December current competitive trends in the Protein Engineering Market include a strong emphasis on digitalization, sustainability, and the integration of AI technologies. Strategic alliances are increasingly shaping the landscape, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may redefine how companies position themselves in the market, emphasizing the importance of agility and responsiveness to emerging trends.

## Recent News & Developments

- **Q2 2024: GenScript Launches New Protein Engineering Market Platform to Accelerate**[**Antibody Drug Discovery**](https://www.marketresearchfuture.com/reports/antibody-drug-discovery-market-12055)GenScript Biotech announced the launch of its next-generation protein engineering platform designed to streamline and accelerate the discovery and optimization of antibody therapeutics, offering enhanced capabilities for pharmaceutical partners.
- **Q2 2024: Codexis Announces Strategic Partnership with Nestlé Health Science for Enzyme Engineering** Codexis entered into a multi-year collaboration with Nestlé Health Science to engineer novel enzymes for use in medical nutrition products, leveraging Codexis’s protein engineering expertise to develop customized solutions.
- **Q2 2024: Thermo Fisher Scientific Opens New Protein Engineering Market Center in Massachusetts** Thermo Fisher Scientific inaugurated a state-of-the-art protein engineering facility in Massachusetts, aimed at expanding its capabilities in biologics development and supporting pharmaceutical clients with advanced protein design services.
- **Q3 2024: Bruker Acquires Protein Engineering Market Startup Evozyne for $150 Million** Bruker announced the acquisition of Evozyne, a Chicago-based protein engineering company specializing in AI-driven enzyme design, to strengthen its biopharma solutions portfolio.
- **Q3 2024: Danaher Launches Protein Engineering Market Innovation Hub in Switzerland** Danaher Corporation opened a new innovation hub in Switzerland focused on protein engineering, aiming to foster collaboration with European biotech firms and accelerate the development of next-generation biologics.
- **Q3 2024: Absci Raises $100 Million in Series D Funding to Expand AI Protein Engineering Market Platform** Absci secured $100 million in Series D financing to scale its AI-powered protein engineering platform, with the goal of accelerating drug discovery partnerships with major pharmaceutical companies.
- **Q4 2024: Eli Lilly and Company Announces FDA Approval for Engineered Insulin Analog** Eli Lilly received FDA approval for its newly engineered insulin analog, developed using advanced protein engineering techniques to improve efficacy and reduce dosing frequency for diabetes patients.
- **Q4 2024: GenScript and Merck KGaA Enter Strategic Collaboration for [Protein Therapeutics](https://www.marketresearchfuture.com/reports/protein-therapeutics-market-10142)** GenScript Biotech and Merck KGaA announced a strategic partnership to co-develop engineered protein therapeutics, combining GenScript’s protein engineering platforms with Merck’s clinical development expertise.
- **Q1 2025: Novo Nordisk Opens New Protein Engineering Market R&D Center in Denmark** Novo Nordisk inaugurated a new research and development center dedicated to protein engineering in Denmark, aiming to accelerate the discovery of next-generation protein-based therapeutics for metabolic diseases.
- **Q1 2025: Thermo Fisher Scientific Acquires Protein Engineering Market Firm Ingenza** Thermo Fisher Scientific completed the acquisition of Ingenza, a UK-based protein engineering company, to enhance its synthetic biology and enzyme engineering capabilities for biopharmaceutical manufacturing.
- **Q2 2025: ElevateBio Announces $200 Million Series C Funding to Advance Cell and Protein Engineering Market Platforms** ElevateBio raised $200 million in Series C funding to expand its cell and protein engineering platforms, supporting the development of novel gene and cell therapies.
- **Q2 2025: Bio-Rad Laboratories Appoints New Head of Protein Engineering Market Division** Bio-Rad Laboratories announced the appointment of Dr. Maria Chen as the new head of its protein engineering division, signaling a strategic focus on expanding its biologics and enzyme engineering business.

## Report Scope

| MARKET SIZE 2024 | 1900.63(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 2124.95(USD Million) |
| MARKET SIZE 2035 | 6484.03(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 11.8% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Amgen (US), Genentech (US), Bristol-Myers Squibb (US), Regeneron Pharmaceuticals (US), GSK (GB), Merck & Co. (US), Novartis (CH), Pfizer (US), Roche (CH) |
| Segments Covered | Application, Technology, End User |
| Key Market Opportunities | Advancements in synthetic biology drive innovation in the Protein Engineering Market. |
| Key Market Dynamics | Technological advancements drive innovation in protein engineering, enhancing applications across pharmaceuticals, agriculture, and industrial sectors. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Protein Engineering Market as of 2025?**
A: The Protein Engineering Market is valued at approximately 1900.63 USD Million in 2024.

**Q: What is the projected market size for the Protein Engineering Market by 2035?**
A: The market is expected to reach a valuation of around 6484.03 USD Million by 2035.

**Q: What is the expected CAGR for the Protein Engineering Market during the forecast period 2025 - 2035?**
A: The market is anticipated to grow at a CAGR of 11.8% from 2025 to 2035.

**Q: Which companies are considered key players in the Protein Engineering Market?**
A: Key players include Amgen, Genentech, Regeneron Pharmaceuticals, and Bristol-Myers Squibb, among others.

**Q: What are the primary applications of protein engineering in the market?**
A: The main applications include Therapeutics, Diagnostics, Research, Industrial Enzymes, and Agricultural Biotechnology.

**Q: How much was the Therapeutics segment valued at in 2024?**
A: The Therapeutics segment was valued at approximately 800.25 USD Million in 2024.

**Q: What is the projected value of the Diagnostics segment by 2035?**
A: The Diagnostics segment is projected to reach about 1080.0 USD Million by 2035.

**Q: Which technology segments are driving growth in the Protein Engineering Market?**
A: Driving technologies include Recombinant DNA Technology, Synthetic Biology, and Protein Design.

**Q: What was the value of the Pharmaceuticals end-use segment in 2024?**
A: The Pharmaceuticals end-use segment was valued at around 570.19 USD Million in 2024.

**Q: What is the expected growth trajectory for the Agricultural Biotechnology segment by 2035?**
A: The Agricultural Biotechnology segment is likely to grow to approximately 540.0 USD Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/protein-engineering-market-691*